重症肢体缺血外科治疗的目标性能目标
本研究回顾性纳入2005年1月至2013年3月在一家三级医疗中心常规实践中接受开放血运重建治疗的315例重症肢体缺血患者,分析其是否符合血管外科学会(SVS)设定的目标性能目标(OPG)。结果显示,符合调整后SVS OPG标准的128例患者(31%)在无截肢生存(AFS)、无主要不良肢体事件+围手术期死亡(MALE+POD)和一期通畅率方面均显著更优。
要点
- 符合SVS OPG标准的患者AFS、MALE+POD和一期通畅率显著更优(P=0.013、P=0.015、P=0.002)。
- 终末期肾病(HR 2.90,95%CI 1.83-4.60,P<0.001)和Fontaine IV期(HR 1.69,95%CI 1.11-2.57,P=0.015)与AFS显著更差相关。
- 男性与MALE+POD显著更优相关(HR 0.64,95%CI 0.46-0.90,P=0.011),而既往无患肢干预与显著更差相关(HR 1.51,95%CI 1.09-2.09,P=0.013)。
核心结论
- 在全部接受外科治疗的重症肢体缺血患者队列中,可以达到SVS设定的OPG疗效,但未符合SVS OPG标准的患者AFS和MALE+POD结果显著更差。
研究设计与样本
- 回顾性纳入2005年1月至2013年3月在一家三级医疗中心接受开放手术(旁路移植或动脉内膜切除)或杂交方法(开放+腔内)血运重建的315例重症肢体缺血患者,平均年龄72岁,平均随访34个月。
主要发现
- 符合调整后SVS OPG标准的128例患者(31%)在AFS、MALE+POD和一期通畅率方面均显著更优(P=0.013、P=0.015、P=0.002)。
- AFS 1年为74%,多变量分析显示终末期肾病(HR 2.90,95%CI 1.83-4.60,P<0.001)和Fontaine IV期(HR 1.69,95%CI 1.11-2.57,P=0.015)与AFS显著更差相关。
- MALE+POD 1年为64%,男性与显著更优结果相关(HR 0.64,95%CI 0.46-0.90,P=0.011),既往无患肢干预与显著更差结果相关(HR 1.51,95%CI 1.09-2.09,P=0.013)。
关键数值与推荐
- 主要终点为无截肢生存(AFS),次要终点为无主要不良肢体事件+围手术期死亡(30天)(MALE+POD),技术终点为一期通畅率。
- 符合调整后SVS OPG标准的患者AFS、MALE+POD和一期通畅率均显著更优(P=0.013、P=0.015、P=0.002)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Based on prospective vein bypass trials for lower leg ischemia, objective performance goals (OPG) were established by the Society for Vascular Surgery (SVS) and are used as a benchmark tool for open and endovascular treatments. This study aims to analyze OPG of all patients with critical limb ischemia (CLI) treated by open revascularization techniques at a tertiary care facility in routine practice. METHODS: From January 2005 to March 2013, 315 patients (mean age 72 years) with CLI were retrospectively included in this study. Inclusion criteria were patients with Fontaine stage III and IV, realized revascularization with open surgical procedures (bypass grafting or endarterectomy), or hybrid method (open + endovascular). Exclusion criteria were primary major amputations, patients with revascularization treatments of the index leg within the last 3 months, and missing aftercare. Primary end point was "amputation-free survival" (AFS), and secondary end point was "freedom from major adverse limb event + perioperative death (30 days)" (MALE + POD) according to the SVS. The technical end point was primary patency. Mean follow-up was 34 months. The following variables were studied: clinical stage (Fontaine), previous interventions, bypass material used, and site of the distal anastomosis. The statistical evaluation and preparation was carried out using the Kaplan-Meier estimator and the log-rank test. A multivariate analysis was performed using the Cox proportional hazards model. A P value ≤0.05 was considered to be statistically significant. RESULTS: A total of 128 patients (31%) fulfilling the adjusted SVS OPG criteria showed significantly better results for AFS, MALE + POD, and primary patency (P = 0.013, P = 0.015, P = 0.002, respectively). Regarding the AFS (1 year: 74%), multivariate analysis displayed significant worse results for patients with end-stage renal disease (hazard ratio [HR] 2.90, 95% confidence interval [CI] 1.83-4.60, P < 0.001) and Fontaine stage IV (HR 1.69, 95% CI 1.11-2.57, P = 0.015). Regarding MALE + POD (1 year: 64%), male patients (HR 0.64, 95% CI 0.46-0.90, P = 0.011) showed a significantly better outcome and patients without previous interventions of the index leg (HR 1.51, 95% CI 1.09-2.09, P = 0.013) showed a significantly worse outcome. CONCLUSIONS: In this study, we were able to show that it is possible to reach the efficacy of OPGs set by SVS in a surgically treated all-comers cohort of CLI patients. Nevertheless, patients who did not fulfill the SVS OPG criteria showed significantly worse results for AFS and MALE + POD.
引用
- Zimmermann A, Balk S, Kuehnl A, et al. Objective Performance Goals for Surgical Treatment of Critical Limb Ischemia. Ann Vasc Surg. 2018. PMID: 30287288. doi:10.1016/j.avsg.2018.07.050
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。